Exicure (NASDAQ:XCUR – Get Free Report) announced its earnings results on Friday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($18.60) by $18.42, FiscalAI reports.
Exicure Trading Down 3.8%
NASDAQ:XCUR traded down $0.05 during midday trading on Friday, reaching $1.26. The company had a trading volume of 15,593 shares, compared to its average volume of 178,948. The firm has a market capitalization of $8.03 million, a price-to-earnings ratio of -0.81 and a beta of 3.65. The stock’s fifty day simple moving average is $1.99 and its 200-day simple moving average is $3.16. Exicure has a 12-month low of $1.18 and a 12-month high of $9.48.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings cut shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.
About Exicure
Exicure is a clinical?stage biotechnology company pioneering the development of next?generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology?based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard?to?reach tissues such as the central nervous system.
The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.
Further Reading
- Five stocks we like better than Exicure
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
